source
- Experts urge FDA to boost transparency of complete response letters and refine master protocol guidanceA recent paper in the Journal of Law and the Biosciences outlines ways the FDA could better disclose complete response letters to the public, aiming to increase transparency for stakeholders. Indu…
- Natera partners with Angiex to evaluate Signatera blood test in AGX101 cancer trialNatera announced a collaboration with biotech Angiex to assess its Signatera circulating tumor DNA blood test in the context of Angiex’s early‑stage clinical trial of AGX101. Angiex, based in Camb…